Invention Grant
US09012496B2 Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof
有权
（R）-1-（2,2-二氟苯并[D] [1,3]二氧杂环戊烯-5-基）-N-（1-（2,3-二羟基丙基）-6-氟-2-（ 1-羟基-2-甲基丙-2-基）-1H-吲哚-5-基）环丙烷甲酰胺及其给药
![Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof](/docs/US/2015-04-21/US09012496B2/abs.jpg.600x600.jpg)
- Patent Title: Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof
- Patent Title (中): （R）-1-（2,2-二氟苯并[D] [1,3]二氧杂环戊烯-5-基）-N-（1-（2,3-二羟基丙基）-6-氟-2-（ 1-羟基-2-甲基丙-2-基）-1H-吲哚-5-基）环丙烷甲酰胺及其给药
-
Application No.: US13942617Application Date: 2013-07-15
-
Publication No.: US09012496B2Publication Date: 2015-04-21
- Inventor: Rossitza Gueorguieva Alargova , Craig Antony Dunbar , Irina Nikolaevna Kadiyala
- Applicant: Vertex Pharmaceuticals Incorported
- Applicant Address: US MA Boston
- Assignee: Vertex Pharmaceuticals Incorporated
- Current Assignee: Vertex Pharmaceuticals Incorporated
- Current Assignee Address: US MA Boston
- Agency: Honigman Miller Schwartz and Cohn LLP
- Agent Heidi M. Berven; Jonathan P. O'Brien
- Main IPC: A61K31/36
- IPC: A61K31/36 ; A61K31/47 ; A61K31/404 ; A61K45/06 ; A61K9/16 ; A61K9/20
![Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof](/abs-image/US/2015/04/21/US09012496B2/abs.jpg.150x150.jpg)
Abstract:
A pharmaceutical composition comprising Compound 1, (R)-1-(2,2-difluorobenzo[d][1,3]dioxo-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide, and at least one excipient selected from: a filler, a disintegrant, a surfactant, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering the pharmaceutical composition of Compound 1 are also disclosed.
Public/Granted literature
Information query
